https://www.selleckchem.com/products/e6446.html
Telavancin is a lipoglycopeptide antibiotic with limited pharmacokinetic data to guide drug dosing in patients receiving haemodialysis. This study characterized telavancin pharmacokinetics in patients receiving haemodialysis. This was a Phase IV, prospective, open-label, single-centre, crossover pharmacokinetic study (ClinicalTrials.gov NCT02392208). Eight subjects with end-stage kidney disease requiring maintenance haemodialysis (mean ± SD 47 ± 20 years, 69.5 ± 17.1 kg) received 5 mg/kg telavancin IV 3 h before starting a 3.5 hour haemod
Like
Comment
Share
